Chemosensitivity testing predicts survival in ovarian cancer

The aim of this study was to assess the use of the MTT assay for chemosensitity testing to identify drug resistance and predict survival in patients with advanced ovarian cancer. Samples of ascitic fluid and/or solid biopsies were taken from 120 patients with FIGO stage III or IV ovarian adenocarcinoma at presentation. Cells were exposed for 48 hours to four concentrations of clinically relevant drugs including platinums, anthracyclines and alkylating agents. Cell survival was measured using the 3-4,5-dimethyl-2, 5-diphenyl tetrazolium bromide (MTT) assay allowing patients to be grouped as "sensitive" or "resistant" in vitro. Clinical data including age, residual disease, histological grade, treatment, response after initial treatment and overall survival were collected. There was a highly significant (p<0.0001) correlation of in vitro sensitivity with in vivo response in the patients who completed their therapy, with an 83% positive predictive accuracy for resistance. This translated in the longer term to an increased survival for the patients found to be sensitive in vitro to their therapy with a 5-year survival rate of 24% compared to 12% for the resistant group (p=0.033). These results suggest that MTT chemonsensitivity testing can predict response in ovarian cancer leading to the prospect of increased survival in this devastating disease by customising therapy to individual patients.

Ovarian cancer; Chemosensitivity; Drug resistance; MTT assay; Clinical samples; Survival

[1] McGuire W. P.: "High-dose chemotherapeutic approaches to ovarian cancer management". Semin. Oneal., 2000, 27 suppl., 41.

[2] Trimble E. L.: "Innovative therapies for advanced ovarian cancer". Semin. Oneal., 2000, 27, Suppl. 7, 24.

[3] Adams M., Calvert A. H., Carmichael J., Clark P. I., Coleman R. E., Earl H. M. et al.: "Chemotherapy for ovarian cancer - a consens us statement on standard practice". Br. J. Cancer, 1998, 78, 1404.

[4] Giaconne G.: "Clinical perspectives on platinum resistance". Drugs, 2000, 59, suppl. 4, 9.

[5] Bodurka-Bevers D., Sun C. C., Gershenson D. M.: "Pharmacoeconomic considerations in treating ovarian cancer". Pharmacoeconomics, 2000, 17, 133.

[6] Wilson J. K., Sargent J. M., Elgie A. W., Hill J. G., Taylor C. G.: "A feasibility study of the MT T assay for chemosensitivity testing in ovarian malignancy". Br. J. Cancer, 1990, 62, 189.

[7] Sargent J., Elgie A., Taylor C., Wilson J., Alton P., Hill J. G.: "The identification of drug resistance in ovarian cancer and breast cancer: application of the MTT assay". Contrib. Gynecol. Obstet., 1994, 19, 64.

[8] Taylor C. G., Sargent J. M., Elgie A. W., Reid F. D. A., Alton P. A., Hill J. G.: "The clinical relevance of chemosensitivity testing in ovarian cancer". Cancer Detect. Prev., 1998, 22, 305.

[9] Sevin B-U., Perras J.P.: "Tumor heterogeneity and in vitro chemosensitivity testing in ovarian cancer". Am. J. Obstet. Gynecol., 1997, 176, 759.

[10] Konency G. K., Crohns C., Pegram M., Felber M., Lude S., Kurbacher C. et al.: "Correlation of drug response with the AT P tumorchemosensitivity assay in primary FIGO stage III ovarian cancer". Gynecol. Oncol., 2000, 77, 258.

[11] Csoka K., Larsson R., Tholander B., Gerdin E., de la Torre M., Nygren P.: "Cytotoxic drug sensitivity testing of tumor cells from patients with ovarian carcinoma using the fluorometric microculture cytotoxicity assay (FMCA)". Gynecol. Oncol., 1994, 54, 163.

[12] Kochli O. R., Sevin B-U., Averette H. E., Haller U.: "Overview of currently used chemonsensitivity test systems in gynecologic malignancies and breast cancer". Contrib. Gynecol. Obstet., 1994, 19, 12.

[13] Andreotti P. E., Cree I. A., Kurbacher C. M., Hartmann D. M., Linder D., Harel G. et al.: "Chemosensitivity testing of human tumors using a microplate adenosine triphosphate luminescence assay: clinical correlation for cisplatin resistance of ovarian cancer". Cancer Res., 1995, 55, 5276.

[14] Piccart M. J., Bertelsen K., James K., Cassidy J., Mangioni C., Simonsen E. et al.: "Randomised intergroup trial of cisplatinpaclitaxel versus cisplatin-cyclophopshamide in women with advanced epithelial ovarian cancer three-year results". J. Natl. Cancer Inst., 2000, 92, 699.

[15] Gallion H. H., Kohn E. C., Mills G. B., Bast R. C.: "Clinical applications of basic science investigations". In: "Ovarian Cancer: Controversies in Management". Gershenson D. M., McGuire W. P., New York, Churchill Livingstone, 1998, 357.

[16] Kurbacher C. M., Untch M., Cree I. A.: "A randomised trial of chemotherapy directed by a tumour chemosensitivity assay versus physician's choice in patients with recurrent platinum-resistant ovarian adenocarcinoma". Lancet Internet publication 1997: http://www.thelancet.com/newlancet/any/author/menu_N0D7.htrnl.